Stockreport

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Haduvio for the treatment of chronic cough in IPF patients Human Abuse Potential Study more than 50 [Read more]